TRICARE Expands Cancer Clinical Trials Demonstration

Publication
Article
OncologyONCOLOGY Vol 13 No 8
Volume 13
Issue 8

TRICARE, the health plan for active duty military personnel (formerly known as CHAMPUS), expanded its cancer clinical trials demonstration so that beneficiaries could enter cancer prevention trials sponsored by the National Cancer Institute

TRICARE, the health plan for active duty military personnel (formerly known as CHAMPUS), expanded its cancer clinical trials demonstration so that beneficiaries could enter cancer prevention trials sponsored by the National Cancer Institute (NCI). The demonstration had previously been limited to cancer treatment trials. The expansion, effective in June, was somewhat of a last-ditch effort to entice more TRICARE beneficiaries into the demonstration so that TRICARE could obtain more data on which to base future decisions. Between January 1996 and August 1998, only 155 TRICARE beneficiaries enrolled in NCI trials, and those were almost exclusively for bone marrow transplants.

Of course, TRICARE has a much better record on covering patient costs of participating in cancer clinical trials than almost any other health plan. Sens. Jay Rockefeller (D-W. Va.) and Connie Mack (R-Fla.) have been trying for years to persuade Congress to pass a bill authorizing a Medicare demonstration that would ensure coverage of patient care costs. No bill has ever gotten out of a Senate committee.

Recent Videos
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Related Content